UA107086C2 - mGluR5 - Google Patents

mGluR5

Info

Publication number
UA107086C2
UA107086C2 UAA201201027A UAA201201027A UA107086C2 UA 107086 C2 UA107086 C2 UA 107086C2 UA A201201027 A UAA201201027 A UA A201201027A UA A201201027 A UAA201201027 A UA A201201027A UA 107086 C2 UA107086 C2 UA 107086C2
Authority
UA
Ukraine
Prior art keywords
lower alkyl
signifies
alkoxyalkyl
independently
hydrogen
Prior art date
Application number
UAA201201027A
Other languages
English (en)
Ukrainian (uk)
Inventor
Георг Єшке
Лотар Ліндеманн
Ерік Вієйра
Йюрген Віхманн
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42358156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107086(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA107086C2 publication Critical patent/UA107086C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным имидазола общей формулы EMBED ISISServer , (I) где R1 означает галоген, низший алкил или низший алкокси; R2 обозначает низший алкил, низший гидроксиалкил или низший алкоксиалкил; R3 обозначает водород, низший алкил, низший гидроксиалкил или алкоксиалкил; Q обозначает -N= или -СН=; R4 представляет собой группу формулы IIa или IIb EMBED ISISServer , IIa EMBED ISISServer , IIb где X, Y и Z независимо представляют собой СН= или -N=, и причем только один из X или Y может быть атомом азота R5 и R6 независимо представляют собой водород, низший алкил, низший гидроксиалкил, низший алкоксиалкил, -(СН2)m-(СО)О-низший алкил, -(СН2)m-S(О)2-низший алкил,-(CH2)m-C(O)-NR'R", и где m = 0-3 и R 'и R' независимо представляют собой водород или низший алкил; а также их фармацевтически приемлемые соли. Выявлено, что соединения общей формулы I являются антагонистами метаботропных глутаматных рецепторов, которые могут применяться в лечении или предупреждении расстройств, опосредованных рецептором mGluR5.
UAA201201027A 2009-07-17 2010-07-14 mGluR5 UA107086C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09165780 2009-07-17
PCT/EP2010/060097 WO2011006910A1 (en) 2009-07-17 2010-07-14 Imidazole derivatives as mglur5 antagonists

Publications (1)

Publication Number Publication Date
UA107086C2 true UA107086C2 (ru) 2014-11-25

Family

ID=42358156

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201201027A UA107086C2 (ru) 2009-07-17 2010-07-14 mGluR5

Country Status (34)

Country Link
US (1) US8334287B2 (ru)
EP (1) EP2456765B1 (ru)
JP (1) JP5667182B2 (ru)
KR (1) KR101431347B1 (ru)
CN (1) CN102471309B (ru)
AR (1) AR077481A1 (ru)
AU (1) AU2010272585B2 (ru)
BR (1) BR112012001092A2 (ru)
CA (1) CA2765921C (ru)
CL (1) CL2012000102A1 (ru)
CO (1) CO6400142A2 (ru)
CR (1) CR20110659A (ru)
CY (1) CY1114186T1 (ru)
DK (1) DK2456765T3 (ru)
EC (1) ECSP12011611A (ru)
ES (1) ES2411467T3 (ru)
HK (1) HK1169397A1 (ru)
HR (1) HRP20130657T1 (ru)
IL (1) IL216746A (ru)
MA (1) MA33386B1 (ru)
MX (1) MX2012000814A (ru)
MY (1) MY156878A (ru)
NZ (1) NZ596810A (ru)
PE (1) PE20120397A1 (ru)
PL (1) PL2456765T3 (ru)
PT (1) PT2456765E (ru)
RS (1) RS52901B (ru)
RU (1) RU2527106C2 (ru)
SG (1) SG178052A1 (ru)
SI (1) SI2456765T1 (ru)
TW (1) TWI423964B (ru)
UA (1) UA107086C2 (ru)
WO (1) WO2011006910A1 (ru)
ZA (1) ZA201109451B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
WO2015143164A1 (en) * 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7138298A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
CN1257894C (zh) 2000-12-04 2006-05-31 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
BRPI0411350A (pt) * 2003-06-12 2006-07-11 Hoffmann La Roche derivados de imidazol substituìdos por heteroarilas como antagonistas de receptores de glutamato
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
BRPI0511678A (pt) * 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
RS50603B (sr) * 2004-06-01 2010-05-07 F. Hoffmann-La Roche Ag. Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism

Also Published As

Publication number Publication date
HRP20130657T1 (en) 2013-08-31
SI2456765T1 (sl) 2013-06-28
IL216746A0 (en) 2012-03-01
PL2456765T3 (pl) 2013-09-30
CA2765921A1 (en) 2011-01-20
WO2011006910A1 (en) 2011-01-20
PT2456765E (pt) 2013-06-20
CO6400142A2 (es) 2012-03-15
AU2010272585B2 (en) 2013-11-07
MY156878A (en) 2016-04-15
HK1169397A1 (en) 2013-01-25
KR101431347B1 (ko) 2014-08-19
RU2012104399A (ru) 2013-08-27
CA2765921C (en) 2017-04-18
DK2456765T3 (da) 2013-05-27
ZA201109451B (en) 2012-08-29
CR20110659A (es) 2012-03-02
CN102471309A (zh) 2012-05-23
NZ596810A (en) 2014-01-31
PE20120397A1 (es) 2012-04-24
AR077481A1 (es) 2011-08-31
AU2010272585A1 (en) 2012-01-19
CN102471309B (zh) 2014-09-03
RU2527106C2 (ru) 2014-08-27
EP2456765A1 (en) 2012-05-30
MA33386B1 (fr) 2012-06-01
EP2456765B1 (en) 2013-05-01
TW201116523A (en) 2011-05-16
ES2411467T3 (es) 2013-07-05
JP5667182B2 (ja) 2015-02-12
US20110015202A1 (en) 2011-01-20
MX2012000814A (es) 2012-03-14
CY1114186T1 (el) 2016-08-31
IL216746A (en) 2015-03-31
CL2012000102A1 (es) 2012-09-07
TWI423964B (zh) 2014-01-21
RS52901B (en) 2014-02-28
BR112012001092A2 (pt) 2020-08-25
ECSP12011611A (es) 2012-02-29
JP2012532913A (ja) 2012-12-20
SG178052A1 (en) 2012-03-29
US8334287B2 (en) 2012-12-18
KR20120032033A (ko) 2012-04-04

Similar Documents

Publication Publication Date Title
MX2009012579A (es) Antagonistas piridil piperidina del receptor de orexina.
IL189987A0 (en) Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
TW200612936A (en) Indole derivatives
TN2011000611A1 (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
MXPA05011670A (es) Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.
MX347423B (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
TW200716547A (en) Piperidin-4-yl-amide derivatives
MX2009008323A (es) Derivados heterociclicos como receptores muscarinicos m3.
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MXPA05010646A (es) Pirazoles sustituidos.
MX2009010727A (es) Heterociclos como antagonistas de orexina.
MX2010002352A (es) Piperazinil pirazinas y piridinas substituidas como antagonistas del receptor 5-ht7.
TW200509920A (en) Imidazole derivatives
IL195747A0 (en) Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
UA107086C2 (ru) mGluR5
MX2011009604A (es) Compuestos 1,1,1-trifluor-2-hidroxipropilo sustituidos por 2,3-diarilo o por heteroarilo.
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
MX2012008147A (es) Derivados de pirrazolopiridina.